Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial of Conventional Versus Hypofractionated Radiation Therapy With Temozolomide for Patients With Newly Diagnosed Glioblastoma

NCT02206230 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT02206230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02206230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial of Conventional Versus Hypofractionated Radiation Therapy With Temozolomide for Patients With Newly Diagnosed Glioblastoma
Lead sponsor
AHS Cancer Control Alberta
Phase
Phase 2
Overall status
Completed
Start date
September 25, 2014
Completion date
February 14, 2023
Enrollment
133 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma